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pAp (3
 -5
  phosphoadenosine phosphate) is a by-product of sulfur
andlipidmetabolismandhasbeenshowntohavestronginhibitory
properties on RNA catabolism. In the present paper we report a
new target of pAp, PARP-1 [poly(ADP-ribose) polymerase 1],
a key enzyme in the detection of DNA single-strand breaks.
We show that pAp can interact with PARP-1 and inhibit its
poly(ADP-ribosyl)ation activity. In vitro, inhibition of PARP-
1 was detectable at micromolar concentrations of pAp and
altered both PARP-1 automodiﬁcation and heteromodiﬁcation of
histones. Analysis of the kinetic parameters revealed that pAp
acted as a mixed inhibitor that modulated both the Km and the
Vmax of PARP-1. In addition, we showed that upon treatment with
lithium, a very potent inhibitor of the enzyme responsible for
pAprecycling,HeLacellsexhibitedareducedlevelofpoly(ADP-
ribosyl)ation in response to oxidative stress. From these results,
we propose that pAp might be a physiological regulator of PARP-
1 activity.
Key words: bipolar disorder, lithium, 3
 -5
  phosphoadenosine
phosphate (pAp), poly(ADP-ribose) polymerase 1 (PARP-1).
INTRODUCTION
pAp (3
 -5
  phosphoadenosine phosphate) is a ubiquitous 3
 -
phosphorylated nucleotide present in organisms from all domains
of life [1]. In mammalian cells, pAp is produced primarily by
the transfer of the sulfate group of PAPS (phosphoadenosine 5
 
phosphosulfate) to various acceptor molecules [2]. This transfer
is catalysed by a number of sulfotransferases and plays a crucial
roleinvariousbiochemicalpathways.Forexample,sulfonationis
involved in the synthesis of sulfate-rich macromolecules such as
heparan sulfate, the activation or inactivation of xenobiotics, the
inactivationofhormonesandcatecholamines,andtheelimination
of end-products of catabolism [3]. Apart from sulfur metabolism,
pAp is also generated from CoA during the transfer of the
4-phosphopantetheine group to ACP (acyl carrier protein) in
fatty acid synthesis or to secondary metabolites such as peptide
antibiotics, surfactin or polyketides [4].
pAp is recycled into AMP and Pi by pAp-phosphatases. pAp-
phosphatases have been described in many organisms, including
bacteria,yeast,plantsandmammals[5–8],andbelongtoaprotein
familydeﬁnedbyastructurallyconservedcoredomain.Acharac-
teristic feature of this protein family is that all members are com-
petitively inhibited by sub-millimolar concentrations of lithium
[9]. As pAp-phosphatase exhibits a very low inhibitory constant,
Ki, for lithium [10], it has been proposed that pAp-phosphatase
could be a molecular target of lithium toxicity. Indeed, overex-
pression of pAp-phosphatase can rescue lithium toxicity both in
yeast and bacteria [11,12]. In addition, lithium is widely used in
thetreatmentofbipolardisorder[13,14],andseveralauthorshave
proposed that pAp-phosphatase could be one of the therapeutic
targets of lithium [9,10]. This hypothesis was supported by the
low Ki of lithium for human pAp-phosphatase [10] compatible
within the range of therapeutic concentrations of lithium in the
plasma of patients (0.8–1 mM). Importantly, the Ki of human
pAp-phosphataseistentimeslowerthanthatofGSK3β (glycogen
synthase kinase 3β), another known target of lithium [15].
The inhibition of pAp-phosphatase by lithium is predicted to
result in the accumulation of intracellular pAp, which in turn
could affect various enzymes and biological processes within
the cells. In fact, pAp inhibits in vitro several proteins, such
as the different sulfotransferases that use PAPS as substrate [3],
NDK (nucleoside diphosphate kinase) [16] and several nucleases
involved in the degradation of RNA. Indeed, the ribonuclease
Xrn1p, responsible in yeast for most cytoplasmic RNA turnover
[17], and oligoribonucleases from Escherichia coli and humans
are strongly inhibited by micromolar amounts of pAp [12,18].
In the present study, we have identiﬁed an additional target
of pAp in human cells. Using pAp-afﬁnity chromatography,
we found that PARP-1 [poly(ADP-ribose) polymerase-1] could
bind selectively to immobilized pAp. We further demonstrated
that PARP-1 activity was strongly inhibited by micromolar
concentrations of pAp. We also showed that lithium treatment
of cells strongly reduced PARP-1 activity in response to oxidative
stress. PARP-1 is a key enzyme in the detection of DNA single-
strand breaks and is crucial for the recruitment of the DNA
repair machinery to these lesions [19]. In the case of severe
DNA damage, PARP-1 is also important in regulating the balance
between DNA repair and cell death [20]. The inhibition of PARP-
1 activity by pAp suggests a link between sulfur and lipid
metabolism and the DNA repair machinery.
MATERIALS AND METHODS
pAp-afﬁnity chromatography on nuclear extracts
pAp-afﬁnity chromatography was performed as described
previously [12]. HeLa cells were grown in spinner ﬂasks in
DMEM (Dulbecco’s modiﬁed Eagle’s medium) containing 7%
Abbreviations used: FBS, fetal bovine serum; NDK, nucleoside diphosphate kinase; pAp, 3 -5  phosphoadenosine phosphate; PARP-1, poly(ADP-ribose)
polymerase 1; PAPS, phosphoadenosine 5  phosphosulfate; Sfn/Orn, small fragment nuclease/oligoribonuclease.
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FBS (fetal bovine serum). Nuclear extracts were prepared
from 10
8 cells as described by Dignam et al. [21]. Extracts
were incubated with cyanogen-bromide-activated agarose beads
coupledtopAp(pAp-agarosebeads;Sigma–Aldrich).Cyanogen-
bromide-activated agarose beads blocked with glycine were used
as a control for non-speciﬁc binding. Nuclear extract was added
to blocked agarose beads and rotated for 2 h at 4◦C to clear
the extract from proteins binding non-speciﬁcally to agarose.
Supernatant was divided equally and added to washed pAp-
agarose beads (pAp-binding fraction) or blocked agarose beads
(control).Afterincubationat4◦Cfor1.5 h,thebeadswerewashed
extensively with wash buffer [50 mM Hepes (pH 7.5), 10 mM
CaCl2,50 mMKCland0.5 MNaCl](tentimesin800 μl).Elution
was performed by adding hot SDS sample buffer followed by
incubation at 65◦C for 15 min. Aliquots (20 μl) of each sample
were analysed by SDS/PAGE (12% gels).
Comparative binding of PARP-1 to AMP- or pAp-agarose
Samples containing 1 μg of partially puriﬁed PARP-1 (Trevigen)
and 100 μgo fB S Ai n5 0μl of binding buffer [5 mM MgCl2,
100 mM NaCl and 50 mM Tris/HCl (pH 8.0)] were incubated
in the presence or absence of 3 mM pAp for 20 min at 4◦C,
then mixed with 5 μl of AMP-agarose or pAp-agarose resin and
incubated for 1 h at 4◦C in Durapore ﬁlter units (Millipore).
Unbound material was removed by centrifugation at 3000 g for
1 min, after which the beads were washed by adding successively
50 μl and 25 μl of binding buffer. These different fractions were
pooled into the ‘unbound fraction’. Elution of bound proteins was
performed by adding a 50 μl aliquot of hot (70◦C) SDS sample
buffer (NuPage, Invitrogen). After 10 min of incubation at 70◦C,
the eluate was collected by centrifugation at 3000 g for
1.5 min. The elution procedure was repeated and the two eluates
werecombinedandreappliedtothebeads.After5 minincubation
at 95◦C, the eluate was collected as described above. A ﬁnal rinse
ofthebeadswasperformedbyadding25 μlofSDSsamplebuffer
at 95◦C and centrifuging for 3 min at 5000 g. All eluates were
pooled into the ‘bound fraction’. Aliquots (10 μl) of unbound
or bound fraction were analysed by SDS/PAGE followed by
detection of PARP-1 by Western blot analysis using monoclonal
anti-PARP-1 antibodies (clone C2-10; BD Pharmingen).
In vitro assays of PARP-1 activity
The activity assay was adapted from a previously published
protocolusedtomeasurePARP-1automodiﬁcation[22].Samples
(50 μl) containing 50 mM Tris/HCl (pH 7.8), 4 mM MgCl2,
200 μM DTT (dithiothreitol), 0.01% Tween 20 and 100 ng of
puriﬁedrecombinanthumanPARP-1(AlexisBiochemicals)were
pre-incubated for 10 min at room temperature (20◦C) in the
presenceorabsenceofpAp.Poly(ADP-ribosyl)ationwasinitiated
byadding50 μlofasolutioncontaining300 ngofDNase-Itreated
salmon sperm DNA (Sigma), 800 μMN A D
+ (Sigma) (400 μM
ﬁnal) and 3.7×10
3 Bq of
32P-radiolabelled NAD
+ (PerkinElmer).
Reactions were performed at room temperature and terminated
by the addition of ice-cold 3-aminobenzamide (Sigma) to a ﬁnal
concentration of 7 mM. Reaction mixtures were immediately
ﬁltered on a nitrocellulose membrane using a slot-blot device.
[
32P]NAD
+ was detected using a storage phosphor screen and
quantiﬁed on a Typhoon® reader using ImageQuant® software.
PARP-1 heteromodiﬁcation activity on histones was measured
using the HT Universal Colorimetric PARP Assay kit with
Histone-Coated Strip wells from Trevigen® according to the
manufacturer’s instructions, except that reactions were stopped
after 45 min instead of 1 h.
In vivo assay of PARP-1 activity
HeLa cells were grown on coverslips in RPMI 1640 medium
containing10%FBS,supplementedwithlithiumchloridefrom0
to5 mM.Oxidativestresswasappliedtothecellsbywashingwith
PBS, and exposing cells to PBS containing 800 μMH 2O2. After
6 minofstress,cellswereimmediatelyﬁxedbyputtingcoverslips
inmethanol/acetoneat −20◦C.Followingthis,immunodetection
of poly(ADP-ribose) was performed according to the method of
Am´ e et al. [22]. Acquisition of images was realized with an
epiﬂuorescencemicroscopeandquantiﬁcationoftheﬂuorescence
signal of at least 100 randomly chosen nuclei was performed with
ImageJ software (NIH). The amount of PARP-1 and its integrity
in cells treated or not with lithium were monitored by Western
blot analysis using a polyclonal antibody from Pharmigen at a
dilution of 1:600.
RESULTS
PARP-1 binds to pAp-agarose
To identify potential targets of pAp in human cells, we
performed pAp-afﬁnity chromatography using nuclear extracts
from HeLa cells. This approach has been successfully employed
to identify the pAp-binding protein Sfn/Orn (small fragment
nuclease/oligoribonuclease) from cytoplasmic extracts of HeLa
cells [12]. pAp-afﬁnity chromatography was performed in the
presence of CaCl2, an efﬁcient inhibitor of pAp-phosphatase
activity. As shown in Figure 1(A), three proteins were
speciﬁcally enriched in the pAp-agarose-bound fraction as
compared with protein bound to control beads. Analysis of these
proteins by in-gel trypsin digestion and LC-MS/MS (tandem
MS) analysis revealed that the two lower bands of 20 and
30 kDa corresponded to NDK and Sfn/Orn respectively. These
two proteins had previously been identiﬁed in cytoplasmic
extracts [12] and are known to be inhibited by pAp [12,16].
The upper band of 110 kDa was identiﬁed as PARP-1. The
identiﬁcation was obtained with three peptides covering 3.8% of
the total mass: VVDRDSEEAEIIRK, HPDVEVDGFSELR and
TLGDFAAEYAK. The overall score of the identiﬁcation, using
ThermoFinnigan Bioworks software, was 50.
Speciﬁcity of the interaction between pAp and PARP-1
To conﬁrm the interaction between PARP-1 and pAp, we
performed pAp-afﬁnity chromatography using a recombinant
enzyme produced in E. coli. As a control for binding speciﬁcity,
we also tested the ability of PARP-1 to bind to AMP-agarose
beads. As shown in Figure 1(B), only limited amounts of PARP-1
bound to AMP-agarose (lane 2). This binding was not affected by
theadditionoffreepAp(lane4)andprobablycorrespondedtothe
non-speciﬁc adsorption of PARP-1 to agarose beads. In contrast,
signiﬁcant amounts of PARP-1 bound to pAp-agarose beads(lane
6)and,moreimportantly,thisbindingwassigniﬁcantlyprevented
by the presence of 3 mM pAp (lane 8). These results suggested
that PARP-1 could interact speciﬁcally with pAp-agarose.
Inhibition of PARP-1 by adenine nucleotides
The interaction between PARP-1 and pAp prompted us to
explore whether pAp might affect the catalytic activity of PARP-
1. PARP-1 is composed of three domains: a DNA-binding
domain, an automodiﬁcation domain and a catalytic domain
[23] responsible for the poly(ADP-ribosyl)ation activity. The
DNA-binding domain senses DNA breaks and subsequently
activates PARP-1 activity [19]. Poly(ADP-ribosyl)ation is a
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Figure 1 Physical interactions between pAp and PARP
(A) SDS/PAGE of pAp-afﬁnity chromatography from HeLa cell nuclear extracts. The gel was
stained with Colloidal Blue. Lane 1, pAp-binding fraction; lane 2, binding on control agarose
beads;lane3,molecularmassmarkers.(B)PARP-1-afﬁnitychromatographywithAMP-agarose
orpAp-agarose.PartiallypuriﬁedPARP-1(1μg)wasincubatedwithAMP-agarose(lanes1–4)
or pAp-agarose (lanes 5–8) in the presence (+) or absence (−) of 3 mM pAp. Detection of
PARP-1 in the bound (B) or unbound (U) fractions was performed by Western blot analysis.
Lane 9, PARP-1 input.
post-translational modiﬁcation of proteins (reviewed in [24]),
which occurs by successive addition of ADP-ribose using
NAD
+ as a substrate. Numerous proteins have been shown to
be poly(ADP-ribosyl)ated by PARP-1, including PARP-1 itself
[25,26].
WeﬁrstassessedtheeffectofpAponPARP-1automodiﬁcation,
namely its ability to auto-poly(ADP-ribosyl)ate in vitro.F o r
this purpose, we measured the incorporation of [
32P]NAD
+ into
poly(ADP-ribose) as described in the Materials and methods,
using a substrate concentration of 400 μM in the presence
or absence of pAp. In the absence of pAp, 1 μgo fP A R P - 1
incorporatedmorethan14 pmolofNAD
+ pers.Thisactivityisin
agreementwiththepreviouslyreportedPARP-1activityfollowing
activation by cleaved DNA [27,28]. We found that in the presence
of 50 μM pAp, poly(ADP-ribosyl)ation activity was reduced by
more than 70%. To determine whether this inhibitory effect was
speciﬁc for pAp, we tested PARP-1 activity in the presence of
various adenine derivatives. As shown in Figure 2, pAp was
by far the strongest inhibitor of PARP-1. With the exception
of ADP-ribose, other adenine derivatives only inhibited PARP-1
to a limited extent. These results are consistent with a previous
study by Niedergang et al. [29], who characterized the effect
of various nucleotides on PARP-1 activity. These authors found
that, among the nucleotides tested, 50 μM ADP-ribose inhibited
approximately 40% of the PARP-1 activity, in good agreement
with the results of the present study (Figure 2). The results of the
present study indicate that pAp was the strongest inhibitor among
all adenine derivatives tested thus far.
We also tested the effect of pAp on PARP-1 activity in the
presence of ATP as several studies have previously shown that
Figure 2 Inhibition of PARP-1 activity by various adenine derivatives
PARP-1 activity was measured as described in the Materials and methods section, in the
presence of 400μM[ 32P]NAD+ with an incubation time of 7 min. Inhibition of PARP-1
activity was measured in the presence of 50μM of the indicated adenine nucleotides. The two
assays shown on the right-hand side were performed in the presence of 1mM ATP. Values
are means+ −S.D. for duplicate experiments, and are expressed as the percentage of activity
without adenine nucleotides. 100% corresponds to 14pmol of incorporated ADP-ribose per s.
*P <0.05; **P <0.01; ***P <0.001, as compared with the control (with or without 1mM
ATP respectively) calculated using Student’s t test.
millimolarconcentrationsofATPinhibitPARP-1activity[28,29].
As shown in Figure 2, PARP-1 activity was reduced by ∼25%
in the presence of 1 mM ATP. However, under these conditions,
pAp,ataconcentrationof50 μM,stillexhibitedaverysigniﬁcant
inhibitory effect on PARP-1 activity.
pAp-mediated PARP-1 inhibition
Figure 3(A) shows PARP-1 activity, measured in the presence
of a ﬁxed substrate concentration of 400 μM[
32P]NAD
+,a sa
function of the pAp concentration. As can be seen, pAp inhibited
the reaction rate of PARP-1 in a dose-dependent manner, with an
apparent inhibitory constant, Ki, in the micromolar range (0.5–
1 μM).
We further tested the effect of pAp on the PARP-1 kinetic
parameters. The initial rate of ADP-ribose incorporation by
PARP-1 was measured in the presence of increasing NAD
+
concentrations at various concentrations of pAp. As shown in
Figure 3(B), the initial rate of poly(ADP-ribosyl)ation could be
ﬁtted using classical Michaelis–Menten kinetics. Figure 3(C)
shows the kinetic parameters calculated from the typical
experimentpresentedinFigure2(B).BothKm andVmax ofPARP-1
were affected by the presence of pAp. From a series of three
independent experiments, we found that the Km of PARP-1 for
NAD
+ varied from 200 to 250 μM in the absence of pAp, from
500 to 550 μM in the presence of 1 μM pAp, and from 900 to
950 μM in the presence of 50 μM pAp. The maximal velocity
Vmax of PARP-1 was also reduced by a factor of 3–4 when pAp
waspresentat50 μMascomparedwithcontrolconditions.These
results suggest a mixed inhibition of PARP-1 by pAp.
pAp inhibitory effect on histone modiﬁcation
In addition to its automodiﬁcation, PARP-1 also modiﬁes various
proteins, and in particular histone H1 [30], in order to recruit the
DNA repair machinery. To test whether pAp could also inhibit
thisheteromodiﬁcation,wemeasuredthepoly(ADP-ribosyl)ation
of histone H1 in the presence of various concentrations of
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Figure 3 Kinetic parameters of pAp inhibition of PARP-1 activity
(A) The kcat, deﬁned as mol of NAD+ incorporated/mol of PARP-1 per s, is expressed as a
functionofthepApconcentration.PARP-1activitywasmeasuredasdescribedinFigure2.Inset:
PhosphorImagerautoradiographyofpoly(ADP-ribosyl)atedPARP-1blottedontoanitrocellulose
membrane. (B) Activity of PARP-1, expressed as pmol of NAD+ incorporated/μg of PARP-1
per s, as a function of the NAD+ concentration, and in the presence of the pAp concentrations
indicated. For each data point ADP-ribose incorporation was measured at 2, 5, 7 and 10 min.
TheactivitywasthendeterminedfromtheslopeoftheADP-riboseincorporatedasafunctionof
time. (C) Kinetic parameters of PARP-1 deduced from the results shown in (B).
pAp. Figure 4 shows a dose-dependent inhibition of the
PARP-1-catalysed histone modiﬁcation by pAp. This inhibition
was comparable with the pAp-mediated inhibition of PARP-1
automodiﬁcation. We therefore propose that pAp is also likely to
inhibit poly(ADP-ribosyl)ation of other PARP-1 targets.
Effect of lithium treatment of cells on poly(ADP-ribosyl)ation
activity
In order to evaluate whether the activity of PARP-1 might be
regulated in vivo, as a response to changes in pAp levels, we
quantiﬁed by immunoﬂuorescence the poly(ADP-ribosyl)ation in
response to oxidative stress in HeLa cells treated or not with
lithium. As lithium is a very potent inhibitor of pAp-phosphatase,
treatment with lithium should result in an increased concentration
Figure 4 pAp inhibition of histone poly(ADP-ribosyl)ation
PARP-1 catalysed poly(ADP-ribosyl)ation of histone H1 was measured as described in the
Materials and methods section in the presence of the indicated concentrations of pAp. The
PARP-1 activity (arbitrary unit) is expressed as a percentage of the activity in the absence of
pAp.
Figure 5 Inhibition of poly(ADP-ribosyl)ation by lithium treatment
(A) PARP-1 was detected by Western blot analysis in protein extracts from HeLa cells treated
or not with lithium. The left-hand lane presents an extract from cells entering apoptosis
as a positive control for PARP-1 cleavage. (B) HeLa cells were treated with the lithium
concentrations indicated for 4days (long) or 30min (short) and were exposed to 800μM
H2O2 for 6min. Poly(ADP-ribosyl)ation was then measured by immunoﬂuorescence detection
of poly(ADP-ribose) polymers as described in the Materials and methods section.
of pAp inside the cells. We veriﬁed by Western blot analysis
that lithium treatment was not affecting the PARP-1 level in the
cell (Figure 5A). This Western blot also shows that there was
no detectable PARP-1 cleavage in cells treated with lithium, the
caspase-induced cleavage of PARP-1 being known to inactivate
the enzyme [31]. After lithium treatment, cells were exposed
to oxidative stress using H2O2, and the resulting poly(ADP-
ribosyl)ation was quantiﬁed by immunoﬂuorescence. As shown
in Figure 5(B), lithium treatment of HeLa cells resulted in a
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dose-dependent decrease of the poly(ADP-ribose) ﬂuorescent
signal intensity. This indicates that the HeLa cells treated with
lithium exhibited a strongly reduced poly(ADP-ribosyl)ation
activityinresponsetooxidativestressascomparedwithuntreated
cells.
AsPARP-1isresponsibleformorethan90%ofthepoly(ADP-
ribosyl)ation activity inside the cells [32,33], this decrease is
probably due to inhibition of PARP-1 activity. Importantly, the
inhibition of PARP-1 activity was only seen after prolonged
lithium treatment, as short-time (30 min) treatment of the cells
(Figure 5B) had no effect on the poly(ADP-ribosyl)ation levels
in response to oxidative stress. This indicates that lithium had no
direct inhibitory effect on the PARP activity or on its activation
by the oxidative stress signals in vivo. We also veriﬁed that,
in vitro, lithium at concentrations up to 5 mM had no effect
on the PARP-1-catalysed poly(ADP-ribosyl)ation of histone H1
(Supplementary Figure S1 at http://www.BiochemJ.org/bj/443/
bj4430485add.htm). We conclude that the strong inhibition of
PARP-1 activity in cells treated by lithium is indirect. We propose
that,incellsexposedtolithium,theinhibitionofpAp-phosphatase
couldresultinprogressiveaccumulationofpApthat,inturn,could
bind to PARP-1 and directly inhibit its enzymatic activity.
DISCUSSION
Searching for potential targets of pAp in human cells, we found
thatPARP-1fromcellextractsboundspeciﬁcallytopAp-agarose.
UsingpuriﬁedPARP-1,wehavedemonstratedthatthisinteraction
wasspeciﬁcandresultedinastronginhibitionofPARP-1activity.
The half-maximum inhibition of enzymatic activity occurred
at pAp concentrations below 1 μM. As adenine derivatives are
known to slightly inhibit PARP-1 activity, we compared the
effect of pAp with that of several other adenine nucleotides.
We found that pAp was a more potent inhibitor than ADP-
ribose,whichwaspreviouslyconsideredasthestrongestinhibitor
among adenine derivatives. We have also shown that both PARP-
1 automodiﬁcation and the heteromodiﬁcation of histones were
similarly affected by pAp. Moreover, characterization of PARP-
1 kinetic parameters showed that pAp affected both the Km and
Vmax, thus indicating a mixed inhibition.
In principle, pAp could target any of the three domains of
PARP-1: the DNA-binding domain, the automodiﬁcation domain
or the catalytic domain [23]. As pAp inhibits both poly(ADP-
ribosyl)ation of histones and PARP-1 automodiﬁcation, it is
unlikely that pAp would act on the automodiﬁcation domain. On
the basis of the homology of pAp with the NAD
+ substrate, it is
probable that pAp binds to the catalytic site of PARP-1. However,
we cannot at present exclude that pAp could interfere with the
activation of PARP-1 by damaged DNA.
As PARP-1 plays a key role in genome maintenance [24], the
inhibition of PARP-1 by pAp may have important physiological
consequences. PARP-1 activation by DNA single-strand breaks
triggers: (i) in the case of limited DNA damage, the recruitment
of repair factors to the DNA damage site [34], and (ii) in the
case of massive DNA damage, the extensive incorporation of
NAD
+ into poly(ADP-ribose) polymers, which can ultimately
lead to NAD
+ depletion and cell death [35]. Given the major role
of PARP-1 in regulating the balance between DNA repair and
cell death, numerous inhibitors have been designed to be used
as anticancer drugs [36,37] or to down-regulate inﬂammatory
responses [38,39]. PARP-1 is also regulated by endogenous
effectors, such as the previously described KIF4 (kinesin family
member 4), which controls the activity-dependent survival of
postmitotic neurons by regulating PARP-1 activity [40]. The
results of the present study indicate that pAp could be another
physiological modulator of PARP-1 activity.
In human cells, pAp is generated during sulfur and lipid
metabolism and is recycled by the pAp-phosphatases. As these
latter enzymes are potently inhibited by lithium, it is assumed
that lithium treatment of cells could affect the intracellular levels
of pAp, and, as a consequence, may ultimately alter the PARP-1
activity. Indeed, we show in the present study, for the ﬁrst time,
that treatment of HeLa cells by lithium inhibits PARP-1 activity
in response to oxidative stress. At 1 mM lithium, which is the
concentration of lithium found in the plasma of patients with
bipolar disorder treated with lithium [41], PARP-1 activity was
reduced by 50% as compared with untreated cells. We further
showedthatthePARP-1inhibitionbylithiumtreatmentisindirect,
as lithium had no effect in vitro on PARP-1 activity and, in vivo,
the lithium-induced inhibition of PARP-1 activity was seen only
under prolonged exposure of the cells to this salt. We propose
that the inhibition of PARP-1 activity by lithium might indirectly
result from the accumulation of intracellular pAp following the
direct lithium inhibition of the pAp-phosphatases.
In human cells, pAp is a by-product of sulfur and lipid
metabolism. The results of the present study suggest that, under
conditions where pAp may accumulate inside the cells, this
nucleotide could modulate the activity of PARP-1. However, to
date, only very limited information on the in vivo concentration
of pAp is available. The standard technique to measure the
pAp concentration relies on HPLC separation of nucleotide, but
cannot detect concentrations of pAp below 50 μM [42]. To our
knowledge, variations in pAp concentrations have only been
measured in yeast under conditions of elevated sulfur metabolic
ﬂux and when the cells were either depleted of pAp-phosphatase
or treated with lithium, a known inhibitor of pAp-phosphatase
[11,18].Inthesesituations,thepApconcentrationsincreasedfrom
undetectable levels to more than 1 mM. Consequently, these stud-
ies are difﬁcult to extrapolate to human cells. A more recent study
attemptedtodetectchangesinpApconcentrationsinbrainsofrats
treatedwithlithium.Theauthorsofthisstudycouldnotdetectany
pAp using the HPLC-based technique described in the study [43].
The most precise measurement of pAp basal levels in various
cell types was performed by Anderson et al. [44] using a
bioluminescent enzymatic measurement of pAp on the basis
of a sulfotransferase from Renilla reniformis. These authors
found approximately 17 nmol of pAp per g of liver tissue from
rabbits, an amount that would correspond to an intracellular pAp
concentration of approximately 0.2–2 μM. The results of the
present study suggest that PARP-1 can be inhibited by pAp at
these concentrations. Given our Ki valuein the micromolar range,
potentialvariationsofpApconcentrationinthemicromolarrange
could signiﬁcantly affect the activity of PARP-1.
In conclusion, we have found that pAp is a strong inhibitor
of PARP-1. We have also shown that treatment of cells with
lithium results in a signiﬁcant inhibition of PARP-1 activity
in response to oxidative stress. We propose that an increase in
intracellular pAp concentrations, occuring either when sulfur
or lipid metabolism is very active or during lithium treatment
(inhibiting pAp-phosphatase), could modulate PARP-1 activity
andthuschangethecellularresponsetoDNAdamage.Ourresults
providenewinsightintotheunderstandingofthemoleculareffect
of lithium in the treatment of bipolar disorder.
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3-5 Phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential
mediator of the lithium-dependent inhibition of PARP-1 in vivo
Elie TOLEDANO*1, Vasily OGRYZKO†, Antoine DANCHIN‡, Daniel LADANT* and Undine MECHOLD*1
*Institut Pasteur, CNRS UMR 3528, Unit´ e de Biochimie des Interactions macromol´ eculaires, D´ epartement de Biologie Strucurale et Chimie, 25–28 rue du Docteur Roux, 75724 Paris
cedex 15, France, †Institut Gustave Roussy, UMR 8126, Unit´ e d’Interactions Mol´ eculaires et Cancer, 94805 Villejuif, France, and ‡AMAbiotics SAS, 5 rue Henri Desbru` eres, 91030
Evry Cedex, France
Figure S1 Lithium effect on PARP-1 activity in vitro
PARP-1activitywasmeasuredusingtheHTUniversalColorimetricPARPassaykitasdescribed
in the Materials and methods section of the main text in the presence of the concentrations of
lithiumindicated.ThePARP-1activity(arbitraryunit)isexpressedasapercentageoftheactivity
measured in the absence of lithium.
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